2024 universal registration document

2.4 Remuneration of Directors and corporate officers

2.4.5 Summary table of the remuneration of Nicolas Hieronimus, Chief Executive Officer

HISTORY OF CONDITIONAL GRANTS OF SHARES (ACAS) TO JEAN-PAUL AGON SINCE HIS APPOINTMENT AS A CORPORATE OFFICER

Grant date	Number of ACAs granted	Performance conditions ⁽³⁾	Grant value (IFRS fair value)	Date of full vesting of all or part of the ACAs	Number of fully vested shares	First possible date of sale of a portion of these ⁽⁴⁾
17 April 2012⁽¹⁾	17 April 2012 ⁽¹⁾ Number of ACAs granted 50,000	17 April 2012 ⁽¹⁾ Performance conditions ⁽³⁾ Yes	17 April 2012 ⁽¹⁾ Grant value (IFRS fair value) 3,853,500	17 April 2012 ⁽¹⁾ Date of full vesting of all or part of the ACAs 18 April 2016	17 April 2012 ⁽¹⁾ Number of fully vested shares 50,000	17 April 2012 ⁽¹⁾ First possible date of sale of a portion of these ⁽⁴⁾ 18 April 2018
26 April 2013⁽¹⁾	26 April 2013 ⁽¹⁾ Number of ACAs granted 40,000	26 April 2013 ⁽¹⁾ Performance conditions ⁽³⁾ Yes	26 April 2013 ⁽¹⁾ Grant value (IFRS fair value) 4,494,800	26 April 2013 ⁽¹⁾ Date of full vesting of all or part of the ACAs 27 April 2017	26 April 2013 ⁽¹⁾ Number of fully vested shares 40,000	26 April 2013 ⁽¹⁾ First possible date of sale of a portion of these ⁽⁴⁾ 27 April 2019
17 April 2014⁽¹⁾	17 April 2014 ⁽¹⁾ Number of ACAs granted 40,000	17 April 2014 ⁽¹⁾ Performance conditions ⁽³⁾ Yes	17 April 2014 ⁽¹⁾ Grant value (IFRS fair value) 4,183,200	17 April 2014 ⁽¹⁾ Date of full vesting of all or part of the ACAs 18 April 2018	17 April 2014 ⁽¹⁾ Number of fully vested shares 40,000	17 April 2014 ⁽¹⁾ First possible date of sale of a portion of these ⁽⁴⁾ 18 April 2020
22 April 2015⁽¹⁾	22 April 2015 ⁽¹⁾ Number of ACAs granted 32,000	22 April 2015 ⁽¹⁾ Performance conditions ⁽³⁾ Yes	22 April 2015 ⁽¹⁾ Grant value (IFRS fair value) 5,167,680	22 April 2015 ⁽¹⁾ Date of full vesting of all or part of the ACAs 23 April 2019	22 April 2015 ⁽¹⁾ Number of fully vested shares 26,432	22 April 2015 ⁽¹⁾ First possible date of sale of a portion of these ⁽⁴⁾ 23 April 2021
20 April 2016⁽²⁾	20 April 2016 ⁽²⁾ Number of ACAs granted 32,000	20 April 2016 ⁽²⁾ Performance conditions ⁽³⁾ Yes	20 April 2016 ⁽²⁾ Grant value (IFRS fair value) 4,938,240	20 April 2016 ⁽²⁾ Date of full vesting of all or part of the ACAs 21 April 2020	20 April 2016 ⁽²⁾ Number of fully vested shares 32,000	20 April 2016 ⁽²⁾ First possible date of sale of a portion of these ⁽⁴⁾ 21 April 2020
20 April 2017⁽²⁾	20 April 2017 ⁽²⁾ Number of ACAs granted 32,000	20 April 2017 ⁽²⁾ Performance conditions ⁽³⁾ Yes	20 April 2017 ⁽²⁾ Grant value (IFRS fair value) 5,340,800	20 April 2017 ⁽²⁾ Date of full vesting of all or part of the ACAs 21 April 2021	20 April 2017 ⁽²⁾ Number of fully vested shares 26,544	20 April 2017 ⁽²⁾ First possible date of sale of a portion of these ⁽⁴⁾ 21 April 2021
17 April 2018⁽²⁾	17 April 2018 ⁽²⁾ Number of ACAs granted 30,000	17 April 2018 ⁽²⁾ Performance conditions ⁽³⁾ Yes	17 April 2018 ⁽²⁾ Grant value (IFRS fair value) 5,285,100	17 April 2018 ⁽²⁾ Date of full vesting of all or part of the ACAs 18 April 2022	17 April 2018 ⁽²⁾ Number of fully vested shares 30,000	17 April 2018 ⁽²⁾ First possible date of sale of a portion of these ⁽⁴⁾ 18 April 2022
18 April 2019⁽²⁾	18 April 2019 ⁽²⁾ Number of ACAs granted 24,000	18 April 2019 ⁽²⁾ Performance conditions ⁽³⁾ Yes	18 April 2019 ⁽²⁾ Grant value (IFRS fair value) 5,430,000	18 April 2019 ⁽²⁾ Date of full vesting of all or part of the ACAs 19 April 2023	18 April 2019 ⁽²⁾ Number of fully vested shares 24,000	18 April 2019 ⁽²⁾ First possible date of sale of a portion of these ⁽⁴⁾ 19 April 2023

At the end of the vesting period, Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred.
The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period.
See the performance conditions described in chapter 7 of this document.
Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the termination of his duties. Jean-Paul Agon has undertaken not to enter into any hedging transactions.

At 31 December 2024, none of the shares granted to Jean-Paul Agon under ACAs Plans were still in their vesting period, because at that date the vesting periods of all the shares granted to him under ACAs Plans in the past had expired.

TABLE OF PERFORMANCE SHARES THAT BECAME AVAILABLE DURING 2024 FOR JEAN‑PAUL AGON

N/A.

2.4.5 Summary table of the remuneration of Nicolas Hieronimus, Chief Executive Officer

In €	Amounts allocated	Amounts paid	Amounts allocated	Amounts paid
	2024		2023
Fixed remuneration	2,000,000	2,000,000	2,000,000	2,000,000
Annual variable remuneration	2,048,500	2,250,000	2,250,000	2,260,000
Exceptional remuneration	-	-	-	-
Remuneration for term of office as a Director	-	-	-	-
Benefits in kind	-	-	-	-
TOTAL	4,048,500	4,250,000	4,250,000	4,260,000

SUMMARY TABLE OF REMUNERATION AND PERFORMANCE SHARES AWARDED TO NICOLAS HIERONIMUS, CHIEF EXECUTIVE OFFICER

In €	2024	2023
Remuneration due in respect of the financial year	Remuneration due in respect of the financial year 2024 4,048,500	Remuneration due in respect of the financial year 2023 4,250,000
Value of performance shares granted during the financial year	Value of performance shares granted during the financial year 2024 5,735,840	Value of performance shares granted during the financial year 2023 6,323,320
TOTAL	TOTAL 2024 9,784,340	TOTAL 2023 10,573,320

HISTORY OF THE STOCK OPTIONS GRANTED TO NICOLAS HIERONIMUS SINCE HIS APPOINTMENT AS A CORPORATE OFFICER THAT CAN STILL BE EXERCISED AT 31 DECEMBER 2024

N/A.

TABLE OF SHARE SUBSCRIPTION OR PURCHASE OPTIONS EXERCISED BY NICOLAS HIERONIMUS DURING FINANCIAL YEAR 2024

N/A.